This $1,078,339 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the "PREPARING INDIGENOUS SCIENTISTS TO LEAD INNOVATIVE SUBSTANCE USE RESEARCH: THE NATIVE CHILDREN'S RESEARCH EXCHANGE SCHOLARS PROGRAM". The grant aims to foster the development of early career Indigenous substance use and disorder researchers, particularly those focused on the impacts and developmental course of problematic...
The National Institute on Drug Abuse (NIDA), under CFDA Program 93.279 - Drug Use and Addiction Research Programs, awarded a $1,965,600 Project Grant to the Regents of the University of Colorado, doing business as the University of Colorado-Denver. The grant titled "Precision Pharmacogenomics and Indigenous Research: A Novel Approach to Tobacco Cessation Efficacy in American Indian Communities" aims to leverage genome-wide and epigenome-wide association studies to better understand the...
The National Institute on Drug Abuse (NIDA) awarded a $873,784 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Arizona State University (ASU) to develop and pilot test an intervention called Project Vuselela (PV). PV integrates peer navigation and family engagement to improve antiretroviral therapy (ART) adherence and opioid substitution therapy (OST) continuation among people who inject drugs (PWID) in Johannesburg, South Africa. The project aims to build...
The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $610,092 Project Grant to National Health Promotion Associates, Inc., a for-profit subchapter S corporation based in White Plains, NY. The grant will fund the development and testing of a hybrid substance use prevention program for upper elementary school students. The program will utilize both online e-learning modules and traditional classroom sessions to teach students...
This $176,326 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports a study to reduce opioid misuse among urban Indigenous young adults in Montana. The principal investigator, Dr. Damian Chase-Begay, will rigorously adapt an evidence-based substance abuse prevention intervention to incorporate traditional ceremonial practices and then test the effectiveness of the adapted intervention at five urban...
This Project Grant award, valued at $282,862 and awarded by the National Science Foundation (NSF) under the Integrative Activities program (CFDA 47.083), supports research at Oklahoma State University (OSU) to investigate the health risks of e-cigarettes and cannabis aerosols, particularly those containing unregulated synthetic cooling agents. The key objectives of this 2-year project are to: (1) quantify exposure and toxicity levels of various vaping aerosol components, (2) assess variability...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $1,226,040 to the Regents of the University of Minnesota to conduct a randomized clinical trial of a culturally-tailored suite of smoking cessation resources for American Indian persons. The key objectives are to: Co-create a culturally-aligned website, "Smokefree.gov for Natives", to serve as the landing page for digital cessation resources tailored for American...
This Project Grant award, funded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program, supports a research project to identify key features of e-cigarette-related social media posts that are associated with high user engagement. The goal is to provide guidance for designing effective vaping prevention messages for future public health campaigns to help communicate the risks of e-cigarette use and prevent youth and young adult initiation...
This Project Grant award of $320,000 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop a smoking and vaping cessation treatment based on the drug candidate cytisine. The goal is to explore the feasibility of delivering cytisine through electronic vape administration (EVA) to help stabilize dopamine release and reduce nicotine self-administration in a mouse model of nicotine addiction. Key activities include...
The National Institute on Drug Abuse (NIDA) awarded a $2,427,126 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Washington State University (WSU) to study culturally adapted Contingency Management (CM) interventions for stimulant use disorders among American Indian and Alaska Native (AI/AN) populations. The grant aims to rapidly implement culturally responsive interventions to address the high rates of fatal poisonings from methamphetamine and fentanyl among...
This Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $2,460,751 to Arizona State University (ASU) to leverage community-engaged research and co-create youth vaping prevention interventions with urban Indigenous communities in the Southwest. The project aims to: 1) identify multilevel risk and protective factors for nicotine and cannabis vaping among urban Indigenous youth; 2) test the efficacy of an adapted evidence-based substance use prevention intervention called "Living in 2 Worlds" to prevent vaping initiation and reduce use, while also examining implementation barriers and facilitators; and 3) advance the science of engaging youth throughout the research process. ASU will collaborate with the Phoenix Indian Center, a Native American-owned non-profit, as a sub-awardee to ensure cultural relevance and community specificity of the intervention. The project period runs from September 1, 2024 to May 31, 2029.